Literature DB >> 18829475

Validation of analytic methods for biomarkers used in drug development.

Cindy H Chau1, Olivier Rixe, Howard McLeod, William D Figg.   

Abstract

The role of biomarkers in drug discovery and development has gained precedence over the years. As biomarkers become integrated into drug development and clinical trials, quality assurance and, in particular, assay validation become essential with the need to establish standardized guidelines for analytic methods used in biomarker measurements. New biomarkers can revolutionize both the development and use of therapeutics but are contingent on the establishment of a concrete validation process that addresses technology integration and method validation as well as regulatory pathways for efficient biomarker development. This perspective focuses on the general principles of the biomarker validation process with an emphasis on assay validation and the collaborative efforts undertaken by various sectors to promote the standardization of this procedure for efficient biomarker development.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18829475      PMCID: PMC2744124          DOI: 10.1158/1078-0432.CCR-07-4535

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  51 in total

Review 1.  Process map proposal for the validation of genomic biomarkers.

Authors:  Federico Goodsaid; Felix Frueh
Journal:  Pharmacogenomics       Date:  2006-07       Impact factor: 2.533

Review 2.  Protein biomarker discovery and validation: the long and uncertain path to clinical utility.

Authors:  Nader Rifai; Michael A Gillette; Steven A Carr
Journal:  Nat Biotechnol       Date:  2006-08       Impact factor: 54.908

3.  Key elements of bioanalytical method validation for small molecules.

Authors:  Surendra Bansal; Anthony DeStefano
Journal:  AAPS J       Date:  2007-03-30       Impact factor: 4.009

4.  Biomarker qualification pilot process at the US Food and Drug Administration.

Authors:  Federico Goodsaid; Felix Frueh
Journal:  AAPS J       Date:  2007-03-23       Impact factor: 4.009

5.  Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Conference report.

Authors:  V P Shah; K K Midha; S Dighe; I J McGilveray; J P Skelly; A Yacobi; T Layloff; C T Viswanathan; C E Cook; R D McDowall
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1991 Oct-Dec       Impact factor: 2.441

6.  Vocabulary for use in measurement procedures and description of reference materials in laboratory medicine.

Authors:  R Dybkaer
Journal:  Eur J Clin Chem Clin Biochem       Date:  1997-02

7.  Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.

Authors:  J Baselga; D Tripathy; J Mendelsohn; S Baughman; C C Benz; L Dantis; N T Sklarin; A D Seidman; C A Hudis; J Moore; P P Rosen; T Twaddell; I C Henderson; L Norton
Journal:  J Clin Oncol       Date:  1996-03       Impact factor: 44.544

Review 8.  Surrogate biochemical markers: precise measurement for strategic drug and biologics development.

Authors:  J W Lee; J D Hulse; W A Colburn
Journal:  J Clin Pharmacol       Date:  1995-05       Impact factor: 3.126

9.  Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

Authors:  Michael C Heinrich; Christopher L Corless; Charles D Blanke; George D Demetri; Heikki Joensuu; Peter J Roberts; Burton L Eisenberg; Margaret von Mehren; Christopher D M Fletcher; Katrin Sandau; Karen McDougall; Wen-bin Ou; Chang-Jie Chen; Jonathan A Fletcher
Journal:  J Clin Oncol       Date:  2006-09-05       Impact factor: 44.544

Review 10.  Workgroup report: Review of genomics data based on experience with mock submissions--view of the CDER Pharmacology Toxicology Nonclinical Pharmacogenomics Subcommittee.

Authors:  John K Leighton; Paul Brown; Amy Ellis; Patricia Harlow; Wafa Harrouk; P Scott Pine; Timothy Robison; Lilliam Rosario; Karol Thompson
Journal:  Environ Health Perspect       Date:  2006-04       Impact factor: 9.031

View more
  68 in total

Review 1.  Application of quantitative pharmacology in development of therapeutic monoclonal antibodies.

Authors:  Mohammad Tabrizi; Cherryl Funelas; Hamza Suria
Journal:  AAPS J       Date:  2010-07-24       Impact factor: 4.009

Review 2.  Recommendations for Use and Fit-for-Purpose Validation of Biomarker Multiplex Ligand Binding Assays in Drug Development.

Authors:  Darshana Jani; John Allinson; Flora Berisha; Kyra J Cowan; Viswanath Devanarayan; Carol Gleason; Andreas Jeromin; Steve Keller; Masood U Khan; Bill Nowatzke; Paul Rhyne; Laurie Stephen
Journal:  AAPS J       Date:  2015-09-16       Impact factor: 4.009

Review 3.  The changing landscape of phase I trials in oncology.

Authors:  Kit Man Wong; Anna Capasso; S Gail Eckhardt
Journal:  Nat Rev Clin Oncol       Date:  2015-11-10       Impact factor: 66.675

Review 4.  Biomarker development for axial spondyloarthritis.

Authors:  Matthew A Brown; Zhixiu Li; Kim-Anh Lê Cao
Journal:  Nat Rev Rheumatol       Date:  2020-06-30       Impact factor: 20.543

5.  Biomarkers of Tobacco Exposure: Summary of an FDA-Sponsored Public Workshop.

Authors:  Cindy M Chang; Selvin H Edwards; Aarthi Arab; Arseima Y Del Valle-Pinero; Ling Yang; Dorothy K Hatsukami
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-11-09       Impact factor: 4.254

Review 6.  Proteomics and biomarkers in clinical trials for drug development.

Authors:  Jung-min Lee; Jasmine J Han; Gary Altwerger; Elise C Kohn
Journal:  J Proteomics       Date:  2011-05-04       Impact factor: 4.044

Review 7.  Advancing computer-aided drug discovery (CADD) by big data and data-driven machine learning modeling.

Authors:  Linlin Zhao; Heather L Ciallella; Lauren M Aleksunes; Hao Zhu
Journal:  Drug Discov Today       Date:  2020-07-11       Impact factor: 7.851

8.  Impact of preanalytic factors on the design and application of integral biomarkers for directing patient therapy.

Authors:  Stephen M Hewitt; Sunil S Badve; Lawrence D True
Journal:  Clin Cancer Res       Date:  2012-03-15       Impact factor: 12.531

9.  Validity of clinical associations of biomarkers in translational research studies: the case of systemic autoimmune diseases.

Authors:  Maria G Tektonidou; Michael M Ward
Journal:  Arthritis Res Ther       Date:  2010-09-27       Impact factor: 5.156

10.  Unblocking blockbusters: using boolean text-mining to optimise clinical trial design and timeline for novel anticancer drugs.

Authors:  Richard J Epstein
Journal:  Cancer Inform       Date:  2009-08-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.